A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.
Fiche publication
Date publication
octobre 2000
Journal
Lung cancer (Amsterdam, Netherlands)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, Meert AP, Vermylen P, Sculier JP,
Lien Pubmed
Résumé
Cisplatin (CDDP) and etoposide (VP16) are considered major standard cytotoxic drugs for small cell lung cancer (SCLC). The present systematic review had as its objective the evaluation of their role, as components of chemotherapy regimens, on survival.
Mots clés
Antineoplastic Agents, Phytogenic, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, Small Cell, drug therapy, Cisplatin, administration & dosage, Etoposide, administration & dosage, Humans, Lung Neoplasms, drug therapy, Prognosis, Randomized Controlled Trials as Topic, Survival Analysis
Référence
Lung Cancer. 2000 Oct;30(1):23-36